Business
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints
About this update from Beam Therapeutics Inc.
[{"type":"text","content":"Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026 Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced in First Half of 2026 Ended 2025 with Estimated $1.25 Billion in Cash, Cash Equivalents and Marketable Securities; Projected Operating Runway Extension into 2029 Supports Anticipated risto-cel Launch and Execution of BEAM-302 Pivotal Development Plan CAMBRIDGE, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced continued progress toward its mission to build a sustainable, predictable model for the advancement of precision genetic medicines, highlighting recent updates for its liver-targeted genetic disease and hematology franchises and strategic priorities in 2026, supported by an extended anticipated operating runway. “Over the past year, we have continued to demonstrate the power and consistency of our base editing platform as we work to redefine what is possible in genetic medicine,” said John Evans, chief executive officer of Beam Therapeutics. “Our approach is rooted in precision and predictability – designing one-time treatments to reverse genetic disease, executing against our portfolio priorities with discipline, and generating differentiated clinical data that compound across programs. As our science and company matures, each milestone strengthens the foundation for the next, enabling us to advance a growing pipeline of programs with increasing confidence and speed. We are now further extending this platform-driven rigor into regulatory execution, including alignment with the FDA on a potential path to accelerated approval for BEAM-302 and a planned BLA submission for risto-cel as early as the end of 2026. Backed by a strong balance sheet and expected cash runway into 2029, we believe we are uniquely positioned to translate scientific innovation into meaningful, lasting benefit for patients with serious diseases.” Recent Pipeline Updates and 2026 Anticipated Milestones Liver-targeted Genetic Disease Franchise Beam is building a platform approach for single-course, precision gene editing therapies ...